{"id":"W2215699720","doi":"10.1200/jco.2015.33.15_suppl.8508","title":"ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Medicine; Lenalidomide; Thalidomide; Internal medicine; Dexamethasone; Clinical endpoint; Multiple myeloma; Bortezomib; Discontinuation; Interim analysis; Refractory (planetary science); Tolerability; Phases of clinical research; Progression-free survival; Gastroenterology; Neutropenia; Oncology; Surgery; Toxicity; Adverse effect; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002064112,0.002269123,0.002025779,0.0005013857,0.0004608677,0.001083085,0.001339718,0.001524368,0.006316986],"category_scores_gemma":[0.001000258,0.0009216992,0.001105994,0.0004491694,0.001243665,0.001194543,0.0005403524,0.003133791,0.001278561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001124452,"about_ca_system_score_gemma":0.00157951,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000951179,"about_ca_topic_score_gemma":0.002998414,"domain_scores_codex":[0.999451,0.0002973103,0.00002589617,0.00008001029,0.00004036514,0.0001054489],"domain_scores_gemma":[0.9994192,0.00009562715,0.0001074392,0.00004088384,0.00002797896,0.0003088322],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9308383,0.03042121,0.002128403,0.0004246193,0.0005522167,0.0001299036,0.0001343841,0.0007716449,0.01087946,0.0001656644,0.001628813,0.02192526],"study_design_scores_gemma":[0.9150476,0.08065423,0.002012108,0.00001267615,0.0001952384,0.00007082702,0.00002076587,0.0003200455,0.0006682383,0.00007761213,0.0009075972,0.0000130533],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9861068,0.00171454,0.0007498695,0.000594183,0.0001740692,0.006220871,0.002286253,0.0001638657,0.001989593],"genre_scores_gemma":[0.9735474,0.001857907,0.003350548,0.001969749,0.0003734686,0.009423318,0.004656404,0.00006237117,0.004758927],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006316986,"threshold_uncertainty_score":0.02113241,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1989119979552419,"score_gpt":0.4908990129290967,"score_spread":0.2919870149738547,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}